Form 4: Elanco CEO Acquires Deferred Stock Units

Elanco Animal Health Inc.'s President and CEO, Jeffrey N. Simmons, acquired 119.0047 deferred stock units as part of an executive compensation plan.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc., acquired 119.0047 Deferred Stock Units (DSUs).
• The transaction occurred on November 28, 2025.
• Each DSU represents the right to receive one share of Company common stock or its cash equivalent.
• DSUs settle in cash or shares of Company common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.
• Following this transaction, Mr. Simmons beneficially owns 18,474.9261 derivative securities (DSUs).
• The implied price per DSU, based on the underlying common stock, was $23.27.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (acquisition of DSUs). While not a direct 'buy' signal, it reflects ongoing executive alignment with company performance and is generally a neutral to slightly positive indicator of management's continued stake in the company's future.

Positives

• The acquisition of deferred stock units aligns the executive's interests with long-term shareholder value.
• The transaction is part of a structured executive compensation plan, indicating stability in management incentives.

Negatives

• No direct negative implications are apparent from this routine compensation-related transaction.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the settlement terms of the deferred stock units, which are tied to future employment termination or a specified future year.

Management Comments

• Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
• Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

This insider transaction is a routine executive compensation event and does not directly reflect broader industry trends. It indicates the company's ongoing use of equity-based incentives for its top management, a common practice across various industries to align executive and shareholder interests.

Comparison to Industry Standards

• The use of Deferred Stock Units (DSUs) as part of executive compensation is a standard practice across many publicly traded companies, including those in the animal health sector.
• Companies like Zoetis Inc. (ZTS) and IDEXX Laboratories, Inc. (IDXX) also utilize various forms of equity awards to incentivize executives, linking their long-term compensation to company performance and shareholder returns.
• The specific number of units granted and their value are typically determined by the company's compensation committee based on performance metrics and market benchmarks for executive pay.

Related Party Transactions

• The acquisition of Deferred Stock Units by Jeffrey N. Simmons, the President, CEO, and Director, constitutes a related party transaction as it involves an executive officer and director of the company.

Stakeholder Impact

• Shareholders: The transaction aligns the CEO's long-term interests with shareholder value through equity ownership.
• Management: Reinforces the CEO's long-term incentive compensation structure.

Next Steps

• Settlement of Deferred Stock Units will occur following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of deferred stock units by the CEO as part of an executive compensation plan. It is not indicative of a significant change in the company's operational or financial performance, nor does it suggest a strategic shift that would warrant an immediate change in investment posture. The transaction primarily serves to align management's long-term interests with shareholders, which is a standard corporate governance practice. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions rather than this specific insider transaction.

Keywords

Elanco Animal Health, ELAN, Jeffrey N. Simmons, Form 4, Deferred Stock Units, DSU, Insider Transaction, Executive Compensation, Beneficial Ownership